adult-onset Still's disease: adult-onset Still disease (AOSD) is a rare inflammatory multisystem disorder characterized clinically by fever of unknown origin, arthralgia or arthritis, hyperleucocytosis, and typical skin rash.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
135 |
4. Check minimum number of eventsNone |
135 |
5. Include endpointsNone |
135 |
6. Filter based on genotype QC (FinnGen only) |
135 |
Control definitions (FinnGen only)
- Control exclude
- ILD_SYST_AUTO_DISEASES
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Rheumatoid lung disease
based on the number of shared cases.
Similar with more cases:
- Seropositive rheumatoid arthritis
- Polyarthropathies
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 998 | 519 | 473 |
| Only index persons | 705 | 370 | 335 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 70.83 | 71.81 | 69.83 |
| Only index persons | 70.05 | 70.59 | 69.45 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 135 | 59 | 76 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
| Median age at first event (years) | 71.11 | 70.62 | 71.49 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 114
- Matched controls
- 1139
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
206.8
98.1
97
30
J99.0*M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
88.4
73
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
105.1
83.4
100
72
A07EC01
ATC
sulfasalazine; oral, rectal
57.3
60.9
73
34
P01BA02
ATC
hydroxychloroquine; oral
41.6
58.1
78
56
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
37.9
51.7
69
44
J99.0
ICD-10 Finland
Rheumatoid lung disease
+∞
44.8
40
*
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
75.2
39.1
43
9
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
58.5
38.2
44
12
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
43.3
38.1
47
18
H02AB06
ATC
prednisolone; systemic
33.2
37.3
108
400
L04AA13
ATC
leflunomide; oral
56.3
37.1
43
12
M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
35.2
32
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
129.7
35.1
36
*
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
59.8
27.2
31
7
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
17.6
26.8
44
39
L04AX01
ATC
azathioprine; systemic
38.0
26.3
33
12
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
21.3
24.7
37
25
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
17.0
24.2
40
35
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.4
21.8
81
283
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
53.9
19.0
22
5
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
50.8
18.0
21
5
L88
ICPC
Rheumatoid/seropositive arthritis
20.6
17.6
26
16
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.5
16.1
67
236
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
29.9
15.3
20
8
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.6
15.0
38
70
L04AA06
ATC
mycophenolic acid; systemic
92.3
15.0
16
*
M01CB01
ATC
sodium aurothiomalate; parenteral
26.6
14.8
20
9
TGC00
NOMESCO Finland
Bronchial lavation
17.8
14.3
22
15
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
18.4
13.2
20
13
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
52.7
12.2
14
*
M05
ICD-10 Finland
Seropositive rheumatoid arthritis
39.5
11.6
14
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
9.6
11.3
23
29
71238
ICD-8 Finland
Rheumatoid arthritis and allied conditions, Arthritis rheumatoides alia definita
48.5
11.2
13
*
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
24.4
11.0
15
7
M01CB03
ATC
auranofin; oral
66.4
10.8
12
*
L04AA01
ATC
[U] ciclosporin; systemic
66.4
10.8
12
*
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
12.4
10.8
19
18
TNB11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in shoulder joint
44.2
10.2
12
*
M05BA04
ATC
alendronic acid; oral
6.2
10.0
28
57
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
24.2
9.6
13
6
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
20.7
9.2
13
7
H02AB07
ATC
prednisone; oral
4.7
9.0
33
91
L04AB01
ATC
etanercept; parenteral
54.3
8.8
10
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
6.4
8.7
23
43
ZX120
NOMESCO Finland
Intravenous
6.1
8.7
24
48
L04AB04
ATC
adalimumab; parenteral
96.9
8.5
9
*
NDL52
NOMESCO Finland
Tenosynovectomy of hand
96.9
8.5
9
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
4.3
8.5
34
102
R06.0
ICD-10 Finland
Dyspnoea
3.5
8.4
49
200
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.0
8.3
37
123
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
36.2
8.2
10
*
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
24.1
8.2
11
5
R50.9
ICD-10 Finland
Fever, unspecified
4.5
8.0
30
84
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
85.4
7.5
8
*
L04AD01
ATC
ciclosporin; systemic
85.4
7.5
8
*
NDG30
NOMESCO Finland
Fusion of wrist, total
85.4
7.5
8
*
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
17.2
7.4
11
7
GX1K5
NOMESCO Finland
Diffusion capacity
+∞
7.4
7
*
M01AC06
ATC
meloxicam; systemic, rectal
3.1
7.2
55
266
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.0
7.2
72
418
XG410
NOMESCO Finland
Flow-volume spirometry
6.7
6.9
17
29
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
7.3
6.9
16
25
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
5.4
6.8
20
43
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
5.5
6.6
19
40
NHM20
NOMESCO Finland
Excision of synovial ganglion of ankle or foot
19.3
6.4
9
5
NHG76
NOMESCO Finland
Arthroplasty of other tarsometatarsal joint
19.3
6.4
9
5
SPAT1292
SPAT
Other function in accordance with SHToL (Finnish classification of nursing interventions)
4.9
6.3
20
47
J990, M058
ICD-10 Finland
NA
+∞
6.3
6
*
L40.5
ICD-10 Finland
Arthropathic psoriasis
+∞
6.3
6
*
WZC30
NOMESCO Finland
Teaching
3.9
6.3
26
80
GD1AD
NOMESCO Finland
Thorax CT examination
7.4
6.3
14
21
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.7
6.1
64
366
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
7.1
6.1
14
22
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
25
19.27
41.54
1.7
1.4
0.2
0.1
iu/ml
—
12
5
33
51
8.24
21.59
3.4
3.2
—
—
—
0
0
22
23
11.23
19.31
1.4
1.4
—
—
—
0
0
16
10
18.02
18.81
1.5
1.1
—
—
—
0
0
53
152
5.09
18.10
1.5
1.2
107.5
25.4
u/ml
2.61
24
50
53
166
4.61
15.97
1.4
1.2
129.5
39.6
iu/ml
1.29
35
61
20
26
8.86
14.84
1.5
1.6
—
—
—
0
0
23
36
7.50
14.62
2.4
1.5
—
—
—
0
0
18
22
9.29
13.97
1.5
1.6
—
—
—
0
0
19
25
8.68
13.93
1.5
1.6
—
—
—
0
0
16
17
10.54
13.71
2.6
1.5
—
—
—
0
0
16
17
10.54
13.71
2.6
1.5
—
—
—
0
0
16
17
10.54
13.71
2.6
1.5
—
—
—
0
0
28
58
5.83
13.55
2.6
1.8
2.7
5.6
ug/l
0.25
28
52
22
36
7.11
13.40
3.2
1.5
—
—
—
0
0
19
27
8.03
13.06
1.4
1.3
—
—
—
0
0
17
21
9.12
13.05
1.6
1.6
—
—
—
0
0
14
16
9.65
11.32
3.6
1.4
—
—
—
0
0
17
27
7.06
10.55
3.5
1.4
—
—
—
0
0
49
189
3.50
10.42
3.3
1.9
—
—
—
0
0
22
47
5.40
10.18
8.4
3.8
4.0
3.9
mmol/l
0.58
22
41
39
132
3.75
10.07
2.1
1.8
—
—
—
0
0
13
16
8.88
9.91
3.8
1.4
—
—
—
0
0
39
134
3.69
9.83
2.3
1.9
—
—
—
0
0
28
77
4.33
9.59
5.9
3.7
54.2
58.4
ml/min/173m2
0.32
13
28
15
23
7.21
9.57
1.3
1.1
—
—
—
0
0
12
15
8.68
9.00
1.0
1.0
—
—
—
0
0
16
30
5.92
8.43
1.4
1.2
1.2
1.2
g/l
0.01
16
30
15
28
5.90
7.92
1.4
1.2
0.2
0.3
g/l
2.08
15
28
13
21
6.74
7.87
1.9
1.5
—
—
—
0
0
75
420
2.77
7.79
2.9
2.3
84.7
77.0
nmol/l
1.30
70
362
93
582
2.92
7.78
7.1
7.2
1.2
1.2
mmol/l
0.09
81
489
60
302
2.78
7.64
10.0
3.8
0.0
0.0
estimate
0.00
18
93
21
56
4.26
7.41
4.3
2.8
1.5
1.0
%
2.32
21
56
81
483
2.69
7.26
5.1
4.0
56.3
36.6
ng/l
0.49
72
362
38
155
3.02
7.07
7.8
6.9
102.4
104.2
mmol/l
1.20
38
150
73
418
2.63
7.05
6.5
3.2
—
—
—
0
0
85
526
2.66
6.96
8.8
3.8
0.0
0.0
estimate
0.00
18
100
86
537
2.66
6.89
8.7
3.8
0.0
0.0
estimate
0.00
19
94
84
531
2.54
6.37
10.1
5.2
0.0
0.0
estimate
0.00
19
100
30
113
3.13
6.35
1.7
2.4
64.4
65.1
g/l
0.18
25
99
23
77
3.40
5.86
5.4
4.0
3.1
2.3
mmol/l
0.57
15
56
10
17
6.27
5.71
4.1
2.8
58.8
60.5
%
—
10
17
26
101
2.95
5.18
4.4
6.5
1.6
1.4
mmol/l
0.62
26
92
21
72
3.27
5.14
4.5
3.9
133.4
127.1
g/l
0.63
21
72
67
417
2.20
4.83
9.7
4.0
—
—
—
0
0
38
190
2.39
4.57
3.5
2.8
1.0
1.0
e6/l
0.01
28
107
13
35
4.00
4.48
1.5
1.4
—
—
—
0
0
7
6
12.20
4.32
1.1
1.0
—
—
—
0
0
54
321
2.14
4.26
4.8
3.1
0.5
0.5
e6/l
0.00
45
242
75
505
2.09
4.25
4.6
4.4
32.4
34.7
g/l
2.47
70
471
12
37
3.46
3.43
1.5
1.4
—
—
—
0
0
17
71
2.60
2.94
1.9
1.3
—
—
—
0
0
6
9
6.91
2.90
4.3
1.2
—
—
—
0
0
6
9
6.91
2.90
4.3
1.2
—
—
—
0
0
6
9
6.91
2.90
4.3
1.2
—
—
—
0
0
6
9
6.91
2.90
4.3
1.2
—
—
—
0
0
40
241
1.94
2.89
2.8
1.7
2.7
1.6
mg/l
0.46
32
193
23
114
2.23
2.76
4.1
2.4
3.5
5.3
ug/l
1.21
23
97
11
38
3.06
2.65
1.8
1.7
—
—
—
0
0
6
13
4.77
2.29
1.0
1.1
—
—
—
0
0
67
503
1.66
2.19
7.2
4.0
—
—
—
0
0
6
14
4.43
2.17
2.0
1.4
—
—
—
0
0
54
384
1.68
2.17
2.6
3.3
2.3
2.3
mmol/l
0.12
48
332
10
39
2.69
1.97
1.4
1.3
—
—
—
0
0
24
139
1.88
1.91
12.7
8.8
—
—
—
0
0
7
22
3.30
1.90
1.3
1.4
—
—
—
0
0
37
250
1.66
1.76
1.8
1.8
1646.9
1163.8
nmol/l
0.87
32
182
5
14
3.67
1.63
4.8
3.9
—
—
—
0
0
6
21
2.94
1.52
1.0
1.1
—
—
—
0
0
63
498
1.50
1.49
3.1
2.4
—
—
—
0
0
10
46
2.27
1.44
5.4
1.8
—
—
—
0
0
15
83
1.91
1.38
1.9
1.6
—
—
—
0
0
12
62
2.03
1.32
3.3
1.8
—
—
—
0
0
6
24
2.57
1.32
1.3
1.6
—
—
—
0
0
8
38
2.17
1.20
1.6
1.1
—
—
—
0
0
8
38
2.17
1.20
1.6
1.1
—
—
—
0
0
6
26
2.37
1.20
1.0
1.1
—
—
—
0
0
19
120
1.68
1.16
4.5
3.3
—
—
—
0
0
9
45
2.07
1.07
3.4
1.6
—
—
—
0
0
5
22
2.32
1.04
1.4
1.6
—
—
—
0
0
5
22
2.32
1.04
1.4
1.6
—
—
—
0
0
0
30
0.00
0.98
0.0
2.2
—
2.5
—
0
21
16
102
1.65
0.95
3.1
4.1
1.2
1.2
mmol/l
0.00
16
89
5
102
0.47
0.94
1.6
2.6
41.4
30.4
u/l
—
5
83
55
469
1.29
0.71
2.1
2.1
87.2
95.4
pmol/l
0.85
34
230
26
200
1.37
0.67
1.3
1.2
0.6
0.9
u/ml
—
8
53
34
275
1.32
0.64
1.4
1.9
624.1
438.3
pmol/l
1.49
29
231
0
20
0.00
0.61
0.0
1.5
—
14.7
—
0
20
8
52
1.57
0.60
1.6
1.3
—
—
—
0
0
31
250
1.31
0.60
4.3
2.3
—
—
—
0
0
114
1082
1.34
0.56
40.9
19.8
79.8
83.3
umol/l
0.74
114
1082
23
183
1.31
0.49
1.9
2.5
2.2
2.3
g/l
0.18
23
165
14
105
1.37
0.43
1.1
1.4
—
—
—
0
0
8
58
1.40
0.42
1.8
2.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
98
934
1.18
0.33
5.0
4.7
1.9
2.0
mu/l
0.49
92
813
115
1117
1.20
0.26
55.0
24.5
128.7
133.5
g/l
3.13
115
1094
5
39
1.29
0.23
1.0
1.5
—
—
—
0
0
5
41
1.23
0.22
1.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
1.1
—
0
5
0
13
0.00
0.21
0.0
1.1
—
39.0
—
0
8
0
13
0.00
0.21
0.0
1.0
—
534.6
—
0
8
33
362
0.88
0.21
4.4
4.6
21.4
22.0
%
0.08
22
185
97
993
0.92
0.13
4.6
4.7
1.4
1.5
mmol/l
0.17
91
892
96
980
0.93
0.10
25.7
16.1
74.2
73.7
ml/min/173m2
0.08
86
811
5
48
1.04
0.09
1.6
1.1
—
—
—
0
0
98
997
0.94
0.08
4.6
4.8
4.4
4.5
mmol/l
0.53
91
907
9
83
1.09
0.07
4.4
3.3
0.2
0.3
e6/l
—
9
83
94
955
0.95
0.06
4.3
4.3
1.4
1.3
mmol/l
1.60
89
852
20
191
1.06
0.03
4.3
3.1
10.0
3.0
e6/l
0.42
11
112
101
1001
1.04
0.02
4.8
5.1
6.1
6.1
mmol/l
0.03
91
894
103
1025
1.02
0.00
5.1
5.4
2.5
2.6
mmol/l
0.54
98
922
0
8
0.00
0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
113.5
—
0
8
0
5
0.00
0.00
0.0
1.0
—
0.3
—
0
5
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
4.4
—
75.3
—
0
7
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
117.2
—
0
5
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint RHEUMAT_LUNG and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| RHEUMAT_LUNG | 4.335 [3.39, 5.55] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.19 |
During the follow-up period (1.1.1998 — 31.12.2019), 221 out of 379 females with RHEUMAT_LUNG died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| RHEUMAT_LUNG | 3.125 [2.41, 4.05] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 209 out of 351 males with RHEUMAT_LUNG died.
Mortality risk
Mortality risk for people of age
years, who have RHEUMAT_LUNG.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.334% | 0.578% |
| 5 | 2.191% | 3.843% |
| 10 | 5.284% | 9.686% |
| 15 | 10.592% | 17.551% |
| 20 | 19.317% | 28.326% |
Relationships between endpoints
↥Index endpoint: RHEUMAT_LUNG – Rheumatoid lung disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data